首页> 外文OA文献 >313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms

【2h】

313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms

机译：313 Tebotelimab的第1期评价，双特异性PD-1 X LAG-3Dart®分子，与Margetuximab组合在先进的HER2 +肿瘤中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Manish Patel; Jason Luke; Erika Hamilton; Bartosz Chmielowski; George Blumenschein; Hedy Kindler; Shakeela Bahadur; Cesar Santa-Maria; Janine Koucheki; Jichao Sun; Sanjeev Kaul; Francine Chen; Xiaoyu Zhang; John Muth; Patrick Kaminker; Paul Moore; Bradley Sumrow; Susanna Ulahannan;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 313?A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART? molecule, in combination with margetuximab in patients with advanced HER2 neoplasms [J] . Manish Patel, Jason Luke, Erika Hamilton, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：313？Tebotelimab的1阶段评估，双特异性PD-1 X LAG-3飞镖？分子，与Margetuximab联合在患有先进海藻的患者中
2. Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054 [J] . Cebada Jorge, Flores Amira, Bandala Cindy, Expert Opinion on Therapeutic Patents . 2020,第7a12期

机译：双特异性抗PD-1 / LAG-3抗体用于治疗先进或转移性实体瘤：US2018326054的专利评价
3. A phase II study of the bispecific antibody MDX-H210 (anti-HER2 |[times]| CD64) with GM-CSF in HER2+ advanced prostate cancer [J] . British Journal of Cancer . 2001,第2期

机译：带有GM-CSF的双特异性抗体MDX-H210（抗HER2 | [倍] | CD64）在HER2 +晚期前列腺癌的II期研究
4. A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer [O] . N D James, P J Atherton, J Jones, 2001

机译：带有GM-CSF的双特异性抗体MDX-H210（抗HER2×CD64）在HER2 +晚期前列腺癌中的II期研究
5. Evaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA) [O] . S. Rutella, S.E. Church, J. Vadakekolathu, 2019

机译：肿瘤微环境的评估鉴定了对Her2 +胃食管腺癌（GEA）中Margetuximab（M）和Pembrolizumab（P）对组合免疫疗法的免疫相关性的免疫相关性

313 A phase 1 evaluation of tebotelimab, a bispecific PD-1 x LAG-3 DART® molecule, in combination with margetuximab in patients with advanced HER2+ neoplasms

著录项

引文网络

相似文献

相关主题

期刊订阅